LIF / LIFR Signaling in Gastric Cancer: A Double‐Edged Sword in Tumor Progression and Therapeutic Resistance
Cancer Medicine · 2025-11 · 14 (21)
DOI: 10.1002/cam4.71315 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 29.10.2025. Verfasst von Daniel Park und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of California San Francisco - Fresno Campus, Fresno, California, USA. Hauptthemen laut MEDLINE: Stomach Neoplasms, Leukemia Inhibitory Factor, Drug Resistance, Neoplasm, Leukemia Inhibitory Factor Receptor alpha Subunit. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gastric cancer (GC) remains a major cause of cancer‐related mortality worldwide, driven by late‐stage diagnoses and poor survival outcomes. Leukemia inhibitory factor (LIF) and leukemia inhibitory factor receptor (LIFR) are increasingly recognized as critical players in GC pathophysiology, though their exact roles are not fully understood. LIF, a multifunctional cytokine in the interleukin‐6 family, signals through the LIFR/gp130 complex and activates oncogenic pathways such as JAK/STAT3, MAPK/ERK, and Hippo‐YAP. Emerging evidence indicates that LIF drives tumor progression by promoting epithelial–mesenchymal transition, immune evasion, and chemoresistance. Clinically, high LIF expression is associated with poor prognosis, peritoneal metastasis, and resistance to chemotherapy and immunotherapy. This review explores the molecular mechanisms of LIF/LIFR signaling in GC, highlighting its potential as a prognostic biomarker and therapeutic target. Mini Abstract Conclusion The LIF/LIFR pathway contributing to gastric cancer is complex with context‐dependent pro‐ versus anti‐tumorigenic roles in GC progression, marking it as a significant biomarker and target for future therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of California San Francisco - Fresno Campus, Fresno, California, USA.
- Department of Internal Medicine, Kaiser Permanente Inland Empire, Fontana, California, USA.
- Translational Bioinformatics Center for Informatics, City of Hope, Duarte, California, USA.
- Department of Internal Medicine, Loma Linda University, Loma Linda, California, USA.
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
- Department of Internal Medicine, Englewood Hospital and Medical Center, Englewood, New Jersey, USA.
ORCID-Profile: Christiana Crook, Daneng Li
Zitieren
APA
Park, D., Kim, K. I., Yuan, Y. C., Shah, P., Zhong, H., Chen, Y. H., Ondrejik, S., Choi, E., Guzman, S., Goes, V., Crook, C., Wang, W., Castillo, D. R., & Li, D. (2025). LIF / LIFR Signaling in Gastric Cancer: A Double‐Edged Sword in Tumor Progression and Therapeutic Resistance. Cancer Medicine, 14(21). https://doi.org/10.1002/cam4.71315
Vancouver
Park D, Kim KI, Yuan YC, Shah P, Zhong H, Chen YH, et al. LIF / LIFR Signaling in Gastric Cancer: A Double‐Edged Sword in Tumor Progression and Therapeutic Resistance. Cancer Medicine. 2025;14(21). doi:10.1002/cam4.71315
BibTeX
@article{Park2025,
author = {Park, Daniel and Kim, Kyung-Il and Yuan, Yate-Ching and Shah, Pranati and Zhong, Hannah and Chen, Yu-Han and Ondrejik, Sharity and Choi, Ellen and Guzman, Sofia and Goes, Vitor and Crook, Christiana and Wang, Wenqi and Castillo, Dani Ran and Li, Daneng},
title = {LIF / LIFR Signaling in Gastric Cancer: A Double‐Edged Sword in Tumor Progression and Therapeutic Resistance},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {21},
doi = {10.1002/cam4.71315}
}
EUVIMED